Profiling CD antigens on leukaemias with an antibody microarray

FEBS Letters

Volumn 583, Issue 11, 2009, Pages 1785-1791

  Barber, Nicole ^a   Gez, Swetlana ^a   Belov, Larissa ^a   Mulligan, Stephen P ^a,b   Woolfson, Adrian ^c   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cluster of differentiation antigen; Leukaemia; Lymphoma; Microarray

Indexed keywords

1 ALPHA HYDROXYVITAMIN D2; 1 ALPHA HYDROXYVITAMIN D5; 19 NOR 1 ALPHA,25 DIHYDROXYVITAMIN D2; ANTINEOPLASTIC AGENT; CALCIFEDIOL; CALCIPOTRIOL; CALCITRIOL; CLADRIBINE; FLUDARABINE; LEUKEMIA ANTIGEN; LYMPHOCYTE ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PURINE NUCLEOSIDE DERIVATIVE; RETINOIC ACID; RO 245531; SEOCALCITOL; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER PROGRAM; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE; HAIRY CELL LEUKEMIA; HUMAN; HYPERCALCEMIA; IMMUNOPHENOTYPING; LEUKEMIA; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; LEUKEMIA;

EID: 67349249991     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.03.018     Document Type: Short Survey

References (51)

1. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organisation (2001), IARC Press, Lyon, France
2. Belov L., de la Vega O., dos Remedios C.G., Mulligan S.P., and Christopherson R.I. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 61 (2001) 4483-4489
3. Belov L., Mulligan S.P., Barber N., Woolfson A., Scott M., Stoner K., Chrisp J.S., Sewell W.A., Bradstock K.F., Bendall L., Pascovici D.S., Thomas M., Erber W., Huang P., Sartor M., Young G.A., Wiley J.S., Juneja S., Wierda W.G., Green A.R., Keating M.J., and Christopherson R.I. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br. J. Haematol. 135 (2006) 184-197
4. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., and van't Veer M.B. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9 (1995) 1783-1786
5. Casasnovas R.O., Slimane F.K., Garand R., Faure G.C., Campos L., Deneys V., Bernier M., Falkenrodt A., Lecalvez G., Maynadie M., and Bene M.C. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 17 (2003) 515-527
6. Paietta E., Goloubeva O., Neuberg D., Bennett J.M., Gallagher R., Racevskis J., Dewald G., Wiernik P.H., and Tallman M.S. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B. Clin. Cytom. 59 (2004) 1-9
7. Guglielmi C., Martelli M.P., Diverio D., Fenu S., Vegna M.L., Cantu-Rajnoldi A., Biondi A., Cocito M.G., Del Vecchio L., Tabilio A., Avvisati G., Basso G., and Lo Coco F. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br. J. Haematol. 102 (1998) 1035-1041
8. Belov L., Huang P., Chrisp J.S., Mulligan S.P., and Christopherson R.I. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J. Immunol. Meth. 305 (2005) 10-19
9. Zamir E., Geiger B., Cohen N., Kam Z., and Katz B.Z. Resolving and classifying haematopoietic bone-marrow cell populations by multi-dimensional analysis of flow-cytometry data. Br. J. Haematol. 129 (2005) 420-431
10. Weinkauff R., Estey E.H., Starostik P., Hayes K., Huh Y.O., Hirsch-Ginsberg C., Andreeff M., Keating M., Kantarjian H.M., Freireich E.J., and Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am. J. Clin. Pathol. 111 (1999) 733-740
11. Avvisati G., Lo Coco F., and Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin. Hematol. 38 (2001) 4-12
12. Warrell Jr. R.P., Frankel S.R., Miller Jr. W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl. J. Med. 324 (1991) 1385-1393
13. Degos L., Chomienne C., Daniel M.T., Berger R., Dombret H., Fenaux P., and Castaigne S. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 336 (1990) 1440-1441
14. Huang M.E., Ye Y.C., Chen S.R., Zhao J.C., Gu L.J., Cai J.R., Zhao L., Xie J.X., Shen Z.X., and Wang Z.Y. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin. Med. J. 100 (1987) 949-953
15. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., and Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
16. Drexler H.G., Quentmeier H., MacLeod R.A., Uphoff C.C., and Hu Z.B. Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk. Res. 19 (1995) 681-691
17. White S.L., Belov L., Barber N., Hodgkin P.D., and Christopherson R.I. Immunophenotypic changes induced on human HL60 leukaemia cells by 1alpha, 25-dihydroxyvitamin D3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk. Res. 29 (2005) 1141-1151
18. Di Noto R., Schiavone E.M., Ferrara F., Manzo C., Lo Pardo C., and Del Vecchio L. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukaemia blast cells. Br. J. Haematol. 88 (1994) 247-255
19. Barber N., Belov L., and Christopherson R.I. All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leuk. Res. 32 (2008) 315-322
20. Breitman T.R., Selonick S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA 77 (1980) 2936-2940
21. .
22. .
23. Killeen N., Davis C.B., Chu K., Crooks M.E., Sawada S., Scarborough J.D., Boyd K.A., Stuart S.G., Xu H., and Littman D.R. CD4 function in thymocyte differentiation and T cell activation. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 342 (1993) 25-34
24. Lagaudriere-Gesbert C., Le Naour F., Lebel-Binay S., Billard M., Lemichez E., Boquet P., Boucheix C., Conjeaud H., and Rubinstein E. Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. Cell Immunol. 182 (1997) 105-112
25. Giblin P.A., and Lemieux R.M. LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. Curr. Pharm. Des. 12 (2006) 2771-2795
26. Kishimoto T. Leucocyte typing VI (1998), Garland Publishing Inc., New York
27. Luan Y., and Xu W. The structure and main functions of aminopeptidase. N. Curr. Med. Chem. 14 (2007) 639-647
28. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
29. Kerr M.A., and Stocks S.C. The role of CD15-(Le(X))-related carbohydrates in neutrophil adhesion. Histochem. J. 24 (1992) 811-826
30. Jefferis R., and Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol. Lett. 82 (2002) 57-65
31. Ridger V.C., Wagner B.E., Wallace W.A., and Hellewell P.G. Differential effects of CD18, CD29, and CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. J. Immunol. 166 (2001) 3484-3490
32. Magnarin M., Spessotto P., Soranzo M.R., Pontillo A., and Zabucchi G. Human neutrophils specifically interact with human monocyte-derived macrophage monolayers. Inflammation 24 (2000) 89-98
33. Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Seguela J.P., Magnaval J.F., Chambon P., Metzger D., Desvergne B., Wahli W., Auwerx J., and Pipy B. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur. J. Immunol. 37 (2007) 1642-1652
34. Zilber M.T., Gregory S., Mallone R., Deaglio S., Malavasi F., Charron D., and Gelin C. CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation. Proc. Natl. Acad. Sci. USA 97 (2000) 2840-2845
35. Seveau S., Keller H., Maxfield F.R., Piller F., and Halbwachs-Mecarelli L. Neutrophil polarity and locomotion are associated with surface redistribution of leukosialin (CD43), an antiadhesive membrane molecule. Blood 95 (2000) 2462-2470
36. Alstergren P., Zhu B., Glogauer M., Mak T.W., Ellen R.P., and Sodek J. Polarization and directed migration of murine neutrophils is dependent on cell surface expression of CD44. Cell Immunol. 231 (2004) 146-157
37. Dahlke M.H., Larsen S.R., Rasko J.E., and Schlitt H.J. The biology of CD45 and its use as a therapeutic target. Leuk. Lymphoma 45 (2004) 229-236
38. Apostolov E.O., Shah S.V., Ok E., and Basnakian A.G. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 826-832
39. van Sorge N.M., van der Pol W.L., and van de Winkel J.G. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61 (2003) 189-202
40. Nair K.S., and Zingde S.M. Adhesion of neutrophils to fibronectin: role of the cd66 antigens. Cell Immunol. 208 (2001) 96-106
41. Scrivener S., Kaminski E.R., Demaine A., and Prentice A.G. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br. J. Haematol. 112 (2001) 959-964
42. Hirano T. Interleukin 6 and its receptor: ten years later. Int. Rev. Immunol. 16 (1998) 249-284
43. Mehta R.G., and Mehta R.R. Vitamin D and cancer. J. Nutr. Biochem. 13 (2002) 252-264
44. Han Z.T., Zhu X.X., Yang R.Y., Sun J.Z., Tian G.F., Liu X.J., Cao G.S., Newmark H.L., Conney A.H., and Chang R.L. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc. Natl. Acad. Sci. USA 95 (1998) 5357-5361
45. Strair R.K., Schaar D., Goodell L., Aisner J., Chin K.V., Eid J., Senzon R., Cui X.X., Han Z.T., Knox B., Rabson A.B., Chang R., and Conney A. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin. Cancer Res. 8 (2002) 2512-2518
46. Blum K.A., Johnson J.L., Niedzwiecki D., Piro L.D., Saven A., Peterson B.A., Byrd J.C., and Cheson B.D. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer 107 (2006) 2817-2825
47. Nabhan C., Gartenhaus R.B., and Tallman M.S. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk. Res. 28 (2004) 429-442
48. Marzo I., Perez-Galan P., Giraldo P., Rubio-Felix D., Anel A., and Naval J. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem. J. 359 (2001) 537-546
49. Baran-Marszak F., Feuillard J., Najjar I., Le Clorennec C., Bechet J.M., Dusanter-Fourt I., Bornkamm G.W., Raphael M., and Fagard R. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 104 (2004) 2475-2483
50. Tam C.S., Wolf M., Prince H.M., Januszewicz E.H., Westerman D., Lin K.I., Carney D., and Seymour J.F. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106 (2006) 2412-2420
51. Ellmark P., Belov L., Huang P., Lee C.S., Solomon M.J., Morgan D.K., and Christopherson R.I. Multiplex detection of surface molecules on colorectal cancers. Proteomics 6 (2006) 1791-1802